Currently, there are 1.92B common shares owned by the public and among those 1.92B shares have been available to trade.
The company’s stock has a 5-day price change of 7.80% and 20.10% over the past three months. NIO shares are trading -46.64% year to date (YTD), with the 12-month market performance down to -35.21% lower. It has a 12-month low price of $3.61 and touched a high of $9.57 over the same period. NIO has an average intraday trading volume of 69.87 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.65%, -11.81%, and -2.60% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of NIO Inc ADR (NYSE: NIO) shares accounts for 9.90% of the company’s 1.92B shares outstanding.
It has a market capitalization of $9.31B and a beta (3y monthly) value of 1.80. The earnings-per-share (ttm) stands at -$1.49. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.34% over the week and 5.55% over the month.
Earnings per share for the fiscal year are expected to increase by 15.28%, and 22.40% over the next financial year. EPS should shrink at an annualized rate of -4.62% over the next five years, compared to 30.22% over the past 5-year period.
Looking at the support for the NIO, a number of firms have released research notes about the stock. Macquarie stated their Neutral rating for the stock in a research note on November 20, 2024, with the firm’s price target at $6.60-$4.80. Macquarie coverage for the NIO Inc ADR (NIO) stock in a research note released on October 28, 2024 offered a Outperform rating with a price target of $6.60. JP Morgan on their part issued Neutral rating on May 15, 2024.
